Loading company…
Mygene provides gene-sequencing tumor detection services in Guangzhou covering lung, colorectal, breast and prostate cancers.
Based in Guangzhou, China, and established in 2015, Mygene offers tumor detection through gene-sequencing technology, with testing carried out by a third-party medical laboratory in Guangzhou. Its tests cover lung, colorectal, breast, gastrointestinal mesenchymal, parenchymal, childhood and prostate tumors. In December 2019 it reached an IVD partnership agreement with Illumina. In April 2017 it completed a Silicon Valley R&D center, and its Chief Scientist Officer, Chunlin Wang, graduated from Stanford University. Its stage is Series C.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in